ArticleNature medicine2026

MAGE-A4/MAGE-A8-targeted TCR-based bispecific T cell engager in recurrent and/or refractory solid tumors: a phase 1 trial.

Martin Wermke et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.